

# Scott Solomon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11333080/publications.pdf>

Version: 2024-02-01

45  
papers

4,134  
citations

236912

25  
h-index

276858

41  
g-index

46  
all docs

46  
docs citations

46  
times ranked

5557  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial—Cardiac Resynchronization Therapy (MADIT-CRT). <i>Circulation</i> , 2011, 123, 1061-1072.	1.6	714
2	Mutations in Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy. <i>New England Journal of Medicine</i> , 2000, 343, 1688-1696.	27.0	646
3	Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 2380-2385.	1.6	501
4	Predictors of Response to Cardiac Resynchronization Therapy in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT). <i>Circulation</i> , 2011, 124, 1527-1536.	1.6	275
5	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	7.1	182
6	Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients. <i>Circulation</i> , 2011, 123, 1763-1770.	1.6	171
7	Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, e34-e61.	1.2	140
8	Familial Dilated Cardiomyopathy Locus Maps to Chromosome 2q31. <i>Circulation</i> , 1999, 99, 1022-1026.	1.6	136
9	Rationale and design of the SOLuble guanylate Cyclase stimuloR in heArT failurE Studies (SOCRATES). <i>European Journal of Heart Failure</i> , 2014, 16, 1026-1038.	7.1	119
10	Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. <i>International Journal of Cardiology</i> , 2017, 244, 229-234.	1.7	113
11	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2325-2335.	27.0	112
12	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2313-2324.	27.0	108
13	The tipping point: Value differences and parallel dorsal—ventral frontal circuits gating human approach—avoidance behavior. <i>NeuroImage</i> , 2016, 136, 94-105.	4.2	73
14	Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). <i>American Heart Journal</i> , 2018, 199, 130-136.	2.7	71
15	Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease. <i>Circulation: Heart Failure</i> , 2015, 8, 448-454.	3.9	68
16	The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. <i>European Heart Journal</i> , 2015, 36, 440-448.	2.2	68
17	BP, Cardiovascular Disease, and Death in the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1554-1562.	6.1	60
18	Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR—HF. <i>European Journal of Heart Failure</i> , 2014, 16, 692-699.	7.1	56

#	ARTICLE	IF	CITATIONS
19	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	52
20	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 313-320.	1.7	49
21	Relative Wall Thickness and the Risk for Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 303-312.	2.8	46
22	Left Atrial Volume and the Benefit of Cardiac Resynchronization Therapy in the MADIT-CRT Trial. <i>Circulation: Heart Failure</i> , 2014, 7, 154-160.	3.9	34
23	Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	32
24	Multicenter Automatic Defibrillator Implantation Trial—“Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. <i>American Heart Journal</i> , 2017, 189, 158-166.	2.7	31
25	High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1303-1309.	7.1	29
26	Endpoints in Heart Failure Drug Development. <i>JACC: Heart Failure</i> , 2020, 8, 429-440.	4.1	28
27	Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients. <i>JAMA Internal Medicine</i> , 2022, 182, 592.	5.1	28
28	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Hypertension</i> , 2018, 31, 407-414.	2.0	26
29	Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 374-382.	4.1	23
30	Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. <i>JAMA Cardiology</i> , 2018, 3, 357.	6.1	22
31	The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. <i>Clinical Trials</i> , 2011, 8, 165-174.	1.6	20
32	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314.	2.7	20
33	Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. <i>Hypertension</i> , 2020, 76, 808-818.	2.7	20
34	Influence of Proteinuria on Cardiovascular Risk and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1725-1727.	2.8	17
35	Early intervention and long-term outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptoms. <i>European Journal of Heart Failure</i> , 2015, 17, 964-970.	7.1	11
36	Heart failure associated with imported malaria: a nationwide Danish cohort study. <i>ESC Heart Failure</i> , 2021, 8, 3521-3529.	3.1	9

#	ARTICLE	IF	CITATIONS
37	Left Ventricular Pacing Threshold and Outcome in MADIT-CRT. Journal of Cardiovascular Electrophysiology, 2014, 25, 1005-1011.	1.7	7
38	Usefulness of Electrocardiographic Left Atrial Abnormality to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure and Left Bundle Branch Block (a) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	1.6	10
39	Comparison of Low Versus High (>40mm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter Automatic Defibrillator) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 70 1053-1058.	1.6	4
40	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. Journal of Cardiac Failure, 2021, 27, 1382-1392.	1.7	3
41	Effect of cardiac resynchronization therapy on the risk of ventricular tachyarrhythmias in patients with chronic kidney disease. , 2017, 22, e12404.		2
42	MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
43	Response to Letter Regarding Article, "Predictors of Response to Cardiac Resynchronization Therapy in The Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT)" Circulation, 2012, 125, .	1.6	0
44	Response to Letter Regarding Article, "Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study" Circulation: Heart Failure, 2015, 8, 1010-1010.	3.9	0
45	Abstract 14054: Soluble ACE2, Cardiac Biomarkers, Structure, Function and Events: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2020, 142, .	1.6	0